Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Co-Administration of Fish Oil With Signal Transduction Inhibitors Has Anti-Migration Effects in Breast Cancer Cell Lines, in vitro.

Davison Z, Nicholson RI, Hiscox S, Heard CM.

Open Biochem J. 2018 Aug 31;12:130-148. doi: 10.2174/1874091X01812010130. eCollection 2018.

2.

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JMW, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2018 Aug 30;20(1):98. doi: 10.1186/s13058-018-0999-6.

3.

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.

Agrawal A, Robertson JF, Cheung KL, Gutteridge E, Ellis IO, Nicholson RI, Gee JM.

Int J Cancer. 2016 Jan 1;138(1):146-59. doi: 10.1002/ijc.29682. Epub 2015 Jul 30.

4.

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.

Stone A, Zotenko E, Locke WJ, Korbie D, Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA, Nicholson RI, Gee JM, Clark SJ.

Nat Commun. 2015 Jul 14;6:7758. doi: 10.1038/ncomms8758.

5.

Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.

Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.

Cancer Res. 2015 Feb 15;75(4):720-31. doi: 10.1158/0008-5472.CAN-14-0652. Epub 2015 Feb 2.

6.

A good drug made better: the fulvestrant dose-response story.

Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM.

Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Review.

PMID:
25457991
7.

Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.

Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.

Breast Cancer Res. 2014 Jan 23;16(1):R12. doi: 10.1186/bcr3604.

8.

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.

McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, Gee JM, Sutherland RL, Musgrove EA, Burgess A, Butt AJ.

Br J Cancer. 2013 Dec 10;109(12):3034-41. doi: 10.1038/bjc.2013.693. Epub 2013 Oct 31.

9.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

PMID:
23900794
10.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

11.

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.

Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA.

Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16.

12.

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, Channon E, Hyman-Taylor P, Nicholson RI, Gee JM.

Breast Cancer Res. 2013 Mar 5;15(2):R18. doi: 10.1186/bcr3393.

13.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

14.

Pro-metastatic tumor-stroma interactions in breast cancer.

Gangadhara S, Barrett-Lee P, Nicholson RI, Hiscox S.

Future Oncol. 2012 Nov;8(11):1427-42. doi: 10.2217/fon.12.134. Review.

PMID:
23148616
15.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.

BMC Cancer. 2012 Oct 6;12:458. doi: 10.1186/1471-2407-12-458.

16.

Synthesis and evaluation of novel anti-proliferative pyrroloazepinone and indoloazepinone oximes derived from the marine natural product hymenialdisine.

White AW, Carpenter N, Lottin JR, McClelland RA, Nicholson RI.

Eur J Med Chem. 2012 Oct;56:246-53. doi: 10.1016/j.ejmech.2012.08.022. Epub 2012 Aug 24.

PMID:
22995819
17.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

18.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

19.

Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.

Taylor KM, Hiscox S, Nicholson RI, Hogstrand C, Kille P.

Sci Signal. 2012 Feb 7;5(210):ra11. doi: 10.1126/scisignal.2002585.

20.

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.

Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N.

Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7.

PMID:
22286314
21.

erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.

Knowlden JM, Gee JM, Barrow D, Robertson JF, Ellis IO, Nicholson RI, Hutcheson IR.

Breast Cancer Res. 2011 Sep 22;13(5):R93. doi: 10.1186/bcr3018.

22.

A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer.

Habashy HO, Powe DG, Abdel-Fatah TM, Gee JM, Nicholson RI, Green AR, Rakha EA, Ellis IO.

Histopathology. 2012 May;60(6):854-63. doi: 10.1111/j.1365-2559.2011.03912.x. Epub 2011 Sep 10. Review.

PMID:
21906125
23.

Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer.

Hiscox S, Nicholson RI.

Expert Rev Endocrinol Metab. 2011 May;6(3):423-435. doi: 10.1586/eem.11.29.

PMID:
30754115
24.

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.

Hutcheson IR, Goddard L, Barrow D, McClelland RA, Francies HE, Knowlden JM, Nicholson RI, Gee JM.

Breast Cancer Res. 2011 Mar 11;13(2):R29. doi: 10.1186/bcr2848.

25.

Therapeutic targeting of tumor-stroma interactions.

Hiscox S, Barrett-Lee P, Nicholson RI.

Expert Opin Ther Targets. 2011 May;15(5):609-21. doi: 10.1517/14728222.2011.561201. Epub 2011 Mar 10. Review.

PMID:
21388336
26.

Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.

Gee JM, Nicholson RI, Barrow D, Dutkowski CM, Goddard L, Jordan NJ, McClelland RA, Knowlden JM, Francies HE, Hiscox SE, Hutcheson IR.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(2):67-77. doi: 10.1515/HMBCI.2011.009.

PMID:
25961242
27.

Acquired endocrine resistance in breast cancer: implications for tumour metastasis.

Hayes E, Nicholson RI, Hiscox S.

Front Biosci (Landmark Ed). 2011 Jan 1;16:838-48. Review.

PMID:
21196206
28.

Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention.

Wadhawan A, Smith C, Nicholson RI, Barrett-Lee P, Hiscox S.

Cancer Treat Rev. 2011 May;37(3):234-41. doi: 10.1016/j.ctrv.2010.08.003. Review.

PMID:
20888696
29.

Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.

Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI.

Eur J Cancer. 2010 Aug;46(12):2187-95. doi: 10.1016/j.ejca.2010.04.012. Epub 2010 May 13. Review.

PMID:
20471823
30.

A novel diffusion cell model for the in vitro assessment of transcutaneous breast cancer therapeutics: effect of permeants on MCF-7 cells cultured within the receptor compartment.

Davison Z, Nicholson RI, Denyer SP, Heard CM.

Eur J Pharm Biopharm. 2010 Aug;75(3):411-7. doi: 10.1016/j.ejpb.2010.03.019. Epub 2010 Apr 2.

PMID:
20363323
31.

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Hiscox S, Barnfather P, Hayes E, Bramble P, Christensen J, Nicholson RI, Barrett-Lee P.

Breast Cancer Res Treat. 2011 Feb;125(3):659-69. doi: 10.1007/s10549-010-0857-4. Epub 2010 Mar 31.

PMID:
20354780
32.

Control of microbial contamination of Franz diffusion cell receptor phase in the development of transcutaneous breast cancer therapeutics.

Davison Z, Nicholson RI, Maillard JY, Denyer SP, Heard CM.

Lett Appl Microbiol. 2009 Oct;49(4):456-60. doi: 10.1111/j.1472-765X.2009.02685.x. Epub 2009 Jun 15.

33.
34.

Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.

Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M.

Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.

PMID:
19288272
35.

Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation.

Hogstrand C, Kille P, Nicholson RI, Taylor KM.

Trends Mol Med. 2009 Mar;15(3):101-11. doi: 10.1016/j.molmed.2009.01.004. Epub 2009 Feb 24.

PMID:
19246244
36.

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.

Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.

Breast Cancer Res Treat. 2010 Jan;119(2):283-93. doi: 10.1007/s10549-009-0345-x. Epub 2009 Feb 24.

PMID:
19238537
37.

SRC as a therapeutic target in breast cancer.

Morgan L, Nicholson RI, Hiscox S.

Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):273-8. Review.

PMID:
19075780
38.

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE.

Cancer Res. 2008 Dec 15;68(24):10238-46. doi: 10.1158/0008-5472.CAN-08-2755.

39.

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.

Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI.

Breast Cancer Res. 2008;10(6):R103. doi: 10.1186/bcr2206. Epub 2008 Dec 4.

40.

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS.

Nature. 2008 Dec 4;456(7222):663-6. doi: 10.1038/nature07483. Epub 2008 Nov 12. Erratum in: Nature. 2009 Feb 26;457(7233):1168.

41.

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival.

Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI, Hurst HC.

J Pathol. 2009 Jan;217(1):32-41. doi: 10.1002/path.2430.

42.

In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin.

Davison Z, Dutkowski C, Gee JM, Nicholson RI, Heard CM.

Pharm Res. 2008 Nov;25(11):2516-25. doi: 10.1007/s11095-008-9665-5. Epub 2008 Jul 12.

PMID:
18622691
43.

ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.

Taylor KM, Vichova P, Jordan N, Hiscox S, Hendley R, Nicholson RI.

Endocrinology. 2008 Oct;149(10):4912-20. doi: 10.1210/en.2008-0351. Epub 2008 Jun 26.

PMID:
18583420
44.

Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO.

Eur J Cancer. 2008 Jul;44(11):1541-51. doi: 10.1016/j.ejca.2008.04.020. Epub 2008 Jun 4.

PMID:
18538561
45.

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.

Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI.

Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21.

PMID:
18493848
46.

Src inhibitors in breast cancer therapy.

Hiscox S, Nicholson RI.

Expert Opin Ther Targets. 2008 Jun;12(6):757-67. doi: 10.1517/14728222.12.6.757 . Review.

PMID:
18479222
47.

Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.

Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO.

Eur J Cancer. 2008 Jan;44(1):73-83. Epub 2007 Nov 26.

PMID:
18035533
48.

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer.

Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI.

J Clin Pathol. 2007 Nov;60(11):1216-21.

49.

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.

Breast Cancer Res Treat. 2008 Sep;111(1):79-91. Epub 2007 Sep 28.

PMID:
17902048
50.

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.

J Clin Oncol. 2007 Oct 20;25(30):4772-8. Epub 2007 Sep 17.

PMID:
17876012

Supplemental Content

Loading ...
Support Center